angiogenic gene therapy

Also found in: Dictionary, Thesaurus, Legal, Financial, Encyclopedia.


Angiogenic GENe Therapy. A clinical trial evaluating the safety & efficacy of an angiogenic gene therapy, Ad5-FGF4 (fibroblast growth factor 4).
Primary endpoint 1-month, 3-month exercise tolerance.
Conclusion Early data indicate that Ad5-FGF4 significantly improves exercise time in treated patients.

Choice in dying An adult appointed by the declarant, under an advance directive executed or made in accordance with the legal provisions, to make health care decisions for the declarant. VA Bd of Medicine, 1997-98 § 54.1-2982
Epidemiology A factor (such as a microorganism, chemical substance, or form of radiation) whose excessive presence, or relative absence (in deficiency states), is essential for the occurrence of a disease.
Health insurance An insurance company representative licensed by the state who solicits, negotiates, or effects insurance contracts and who provides services to the policyholder for the insurer.
Infomatics A small mobile piece of computer software that can send itself across a computer network and perform a task on a remote machine.
Medspeak A thing capable of producing an effect.
Military A code term for a biological substance that can be used as a weapon of mass destruction.
Nutrition A substance added to a food to change a physical property.
Pharmaceutical industry An authorised person who acts on behalf of or at the direction of a manufacturer, distributor, or dispenser, not including a common or contract carrier, public warehouseman, or employee of the carrier warehouseman. VA Bd of Pharmacy, 7/97.
Pharmacology Any substance capable of producing a physical, chemical or biologic effect.
Virology An unidentified virus or pathogen.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.

angiogenic gene therapy

Cardiology An investigational therapy that delivers a growth factor gene to diseased coronary arteries evoking growth factor production and stimulating angiogenesis and formation of blood vessels that bypass occluded coronary arteries
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.
Mentioned in ?
References in periodicals archive ?
- The US FDA has granted Fast Track designation for the Phase 3 clinical investigation of US-based biotechnology company Angionetics Inc.'s Generx [Ad5FGF-4] cardiovascular angiogenic gene therapy as a one-time treatment for improving exercise tolerance in patients who have angina that is refractory to standard medical therapy and not amenable to conventional revascularisation procedures (coronary artery bypass surgery and percutaneous coronary intervention and stents), the company said.
"The addition of this new gene broadens our portfolio of therapeutic genes and expands the range of commercial opportunities for Collateral in the field of cardiovascular angiogenic gene therapy," said Christopher J.
(San Diego, CA; 858-794-3420) announced the issuance of United States Patent 6,174,871 entitled "Gene Therapies for Enhancing Cardiac Function," which is directed to angiogenic gene therapy methods for treating heart disease.